Anavex Life Sciences faces a pivotal EU regulatory decision for its Alzheimer’s drug blarcamesine, with a binary outcome likely to move the stock. AVXL’s Phase 2B/3 trial met cognitive but not ...
Just ahead of the EMA setting out its latest thinking on regulation in the new era of artificial intelligence (AI), the industry has put forward its position on how to ensure AI rules enable, rather ...
A novel non-antibiotic approach to diarrhea treatment is important because there are no FDA-approved drugs to treat general diarrhea in dogs, the second most common reason for visits to veterinary ...
BARCELONA, Spain — The challenges of accessing oncology drugs are not limited to low- and middle-income countries but also affect high-income nations. This was highlighted here by experts at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback